| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 45.82 mm | 45.82 mm | 45.82 mm | 45.82 mm | 45.82 mm | 45.82 mm |
| Cash burn (monthly) | (no burn) | 991.50 k | 6.89 mm | 7.37 mm | (no burn) | 4.05 mm |
| Cash used (since last report) | n/a | 3.99 mm | 27.72 mm | 29.64 mm | n/a | 16.29 mm |
| Cash remaining | n/a | 41.84 mm | 18.10 mm | 16.19 mm | n/a | 29.54 mm |
| Runway (months of cash) | n/a | 42.2 | 2.6 | 2.2 | n/a | 7.3 |
| 13F holders | Current |
|---|---|
| Total holders | 61 |
| Opened positions | 14 |
| Closed positions | 17 |
| Increased positions | 12 |
| Reduced positions | 18 |
| 13F shares | Current |
|---|---|
| Total value | 94.47 bn |
| Total shares | 53.58 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Atlas Venture Life Science Advisors | 5.84 mm | $19.85 bn |
| Ventures GP III, L.L.C. Vida | 5.02 mm | $18.46 mm |
| Atlas Venture Fund XII | 4.81 mm | $57.03 mm |
| Northpond Ventures | 4.21 mm | $14.33 bn |
| AMGN Amgen | 3.21 mm | $38.03 mm |
| Northpond Ventures | 2.83 mm | $26.56 mm |
| Biotechnology Value Fund L P | 2.74 mm | $21.56 mm |
| Flynn James E | 2.05 mm | $0.00 |
| Siren, L.L.C. | 1.99 mm | $6.77 bn |
| Invus Global Management | 1.83 mm | $7.33 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 19 Dec 24 | Magovcevic Ivana | Common Stock | Buy | Acquire P | No | No | 1.68 | 5,000 | 8.40 k | 222,687 |
| 19 Dec 24 | Haeberlein Samantha L. Budd | Common Stock | Buy | Acquire P | No | No | 1.71 | 12,000 | 20.52 k | 12,000 |
| 18 Dec 24 | Magovcevic Ivana | Common Stock | Buy | Acquire P | No | No | 1.67 | 5,000 | 8.35 k | 217,687 |
| 5 Dec 24 | Magovcevic Ivana | Common Stock | Buy | Acquire P | No | No | 2.34 | 5,000 | 11.70 k | 212,687 |
| 5 Jun 24 | Thistle Mary | Stock Option Award Common Stock | Grant | Acquire A | No | No | 3.38 | 18,068 | 61.07 k | 18,068 |
